Eisai Strengthens Lenvatinib's Clinical Profile with New ASCO 2026 Data
Event summary
- Eisai presents new real-world evidence comparing Lenvatinib to Dabrafenib + Trametinib in BRAF-mutated differentiated thyroid cancer at ASCO 2026.
- Additional analysis from the CLEAR trial examines efficacy outcomes by patterns of progression in advanced renal cell carcinoma.
- Eisai also highlights cardiac safety assessments for E7386, a CREB-binding protein inhibitor, in early-stage oncology development.
- Lenvatinib is recommended as a preferred Category 1 systemic therapy regimen for progressive, radioactive iodine-refractory DTC in NCCN Guidelines.
- Eisai and Merck's strategic collaboration for Lenvatinib's co-development and co-commercialization continues.
The big picture
Eisai's presentation at ASCO 2026 underscores its focus on deepening the clinical evidence for Lenvatinib, a key drug in its oncology portfolio. The data reinforces Lenvatinib's role in treating difficult-to-treat cancers, aligning with Eisai's strategic emphasis on Neurology and Oncology. The collaboration with Merck further strengthens its position in the competitive oncology market, particularly in combination therapies.
What we're watching
- Clinical Validation
- Whether the real-world evidence for Lenvatinib in BRAF-mutated thyroid cancer will expand its approved indications.
- Combination Therapy
- How the CLEAR trial analysis will influence the adoption of Lenvatinib plus Pembrolizumab in renal cell carcinoma.
- Pipeline Progress
- The pace at which Eisai advances E7386 through clinical development, given its potential to inhibit the Wnt/β-catenin pathway.
Related topics